Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.
They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).
While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.
To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.
We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle. Our clients include Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer and Novartis.
News & insights
Blog Post: 15 SEPTEMBER 2021
The Court of Appeal (Birss LJ, Floyd LJ and Phillips LJ) handed down its judgment in Fibrogen v Akebia on 24 August 2021, overturning Arnold LJ (another Court of Appeal judge) on his judgment on…Read more
Publications: 31 AUGUST 2021
On 20 August 2021, the Standing Committee of the National People’s Congress adopted the Personal Information Protection Law (the PIPL), the long-awaited and first omnibus personal data protection…Read more
Blog Post: 13 AUGUST 2021
The European Commission has announced that the Clinical Trials Regulation, already enacted in 2014, will take effect on 31 January 2022.Read more